| Trial ID: | L4164 |
| Source ID: | NCT01345734
|
| Associated Drug: |
Liraglutide
|
| Title: |
Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes
|
| Acronym: |
Lead-Ph
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide
|
| Outcome Measures: |
Primary: Incidence of serious adverse drug reactions (SADRs), Week 0, week 26 | Secondary: Incidence of adverse drug reactions (ADRs), Week 0, week 26|Incidence of serious adverse events (SAEs), Week 0, week 26|Frequency of hypoglycaemic episodes, Week 0, week 26|Change in HbA1c (glycosylated haemoglobin)", Week 0, week 26
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1056
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2011-09-01
|
| Completion Date: |
2013-07-26
|
| Results First Posted: |
|
| Last Update Posted: |
2018-12-11
|
| Locations: |
Novo Nordisk Investigational Site, Manilla, 1605, Philippines
|
| URL: |
https://clinicaltrials.gov/show/NCT01345734
|
